| Biotech startup Bicara Therapeutics secured $108M in Series B funding co-led by Red Tree Venture Capital and RA Capital Management. The Cambridge, Massachusetts-based startup is combining target therapies and immunotherapies into single precision antibodies to treat cancer. The fresh capital infusion will help the firm to advance the clinical pipeline of its lead drug candidate BCA101, commence human trials, and grow team size.
|